NEFL and multiple system atrophy: Until now, there are no other cerebrospinal fluid (CSF) or blood biomarkers that can potentially discriminate PD from MSA and PSP (Aerts et al., 2012; Chahine et al., 2014), with the exception of neurofilament light (NfL) chain (Hansson et al., 2017).